A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer

[1]  P. Conte,et al.  Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. , 2009, The oncologist.

[2]  F. Xie,et al.  The role of cellular oxidative stress in regulating glycolysis energy metabolism in hepatoma cells , 2009, Molecular Cancer.

[3]  J. Lee,et al.  Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.

[4]  Alvin T. Lo,et al.  Molecular mechanisms underlying selective cytotoxic activity of BZL101, an extract of Scutellaria barbata, towards breast cancer cells , 2008, Cancer biology & therapy.

[5]  S. Franco,et al.  Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer , 2007, Breast Cancer Research and Treatment.

[6]  D. Newman,et al.  Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.

[7]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[8]  M. Campbell,et al.  In vitro anticancer activity of twelve Chinese medicinal herbs , 2005, Phytotherapy research : PTR.

[9]  Mark S Butler,et al.  The role of natural product chemistry in drug discovery. , 2004, Journal of natural products.

[10]  David J Newman,et al.  Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.

[11]  F. Hamdy,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[12]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[13]  D. Tripathy,et al.  Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro. , 2002, Anticancer research.